Corbus Pharmaceuticals after lenabasum: can a wounded cannabinoid bet become a diversified immunology platform?
When lenabasum failed two high-profile studies in 2020, Corbus Pharmaceuticals went from a single-asset systemic sclerosis story to a case study in biotech rein…